Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

impact-2

  • Home
  •  
  • impact-2



  • Most Read
  • Latest Comments
  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Emyria Expands Into Victoria as Medibank Backs Mental Health Programs
    Emyria Expands Into Victoria as Medibank Backs Mental Health Programs
    • News

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • News

    Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial

    Biotechnology company Emyria (ASX: EMD), which develops treatments for mental health and neurological conditions, has newly inaugurated its treatment facility Empax Centre. The centre has been selected as a key site for a clinical trial sponsored by New York-based Transcend Therapeutics.  The trial will evaluate the safety and efficacy of methylone, a novel rapid-acting neuroplastogen

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.